An open trial of zimelidine in patients with endogenous depression.
13 patients with endogenous depression, who had failed to obtain a lasting response to other antidepressant drugs or to electroconvulsive therapy, were treated with zimelidine. 3 showed a marked, and 3 a mild improvement. Side effects were minimal.
D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001977:Brompheniramine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D011725:Pyridines / Q000627:therapeutic use*; D015031:Zimeldine
D000928:Antidepressive Agents; D011725:Pyridines; D015031:Zimeldine; D001977:Brompheniramine